Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: December 2007
-
Practising Law Institute (PLI) will be holding its 2nd Annual Patent Law Institute on January 14-15, 2008 in New York, NY and on January 28-29, 2008 in San Francisco, CA. A live webcast of the San Francisco session will also be available. The two-day conference consists of six one-hour plenary sessions of broad interest to…
-
By Robert Dailey — Just two years ago, the world of patent law (and maybe even Michael Crichton) waited for the Supreme Court to reconsider the standard for patentable subject matter – at least with respect to process claims. The Supremes had granted cert. on the following question: "Whether a patent instructing a…
-
By Suresh Pillai — Last month, Morphotek, Inc., a subsidiary of Eisai Co., Ltd. based in Exton, Pennsylvania, announced that it had been granted U.S. Patent No. 7,235,643 ("Antibodies and methods for generating genetically altered antibodies with high affinity," issued June 26, 2007). This is the eleventh U.S. Patent awarded to Morphotek, Inc.…
-
By Donald Zuhn — The Intellectual Property Owners Association (IPO) announced today that IPO President Marc Adler has written a letter to Senator Patrick Leahy (at right), urging the Chairman of the Committee on the Judiciary to delete a provision from the Senate Patent Reform Act (S.1145) that would require applicants to submit…
-
By Jason Derry — Eisai Co., Ltd. and MGI PHARMA, Inc. have announced that Eisai will acquire MGI PHARMA for approximately $3.9 billion. Eisai is a research-based company focusing on discovery, development, and marketing of therapeutic products in the fields of neuroscience, gastrointestinal disorders, and oncology. MGI PHARMA is a biopharmaceutical company that…
-
By Donald Zuhn — Last month, the Federal Circuit affirmed a District Court’s finding on summary judgment that Merck & Co., Inc. had not obtained favorable rulings in two prior proceedings by fraud. The prior proceedings included an infringement suit involving U.S. Patent Nos. 5,573,780 (the ‘780 patent) and 5,690,962 (the ‘962 patent)…
-
By Kevin E. Noonan — The Office of Management and Budget (OMB), the part of the Executive Branch charged with, among other things, assessing the economic impact of rules and regulations promulgated by various agencies of the Federal government, today issued its decision regarding the U.S. Patent and Trademark Office’s "Changes to Information…
-
By Kevin E. Noonan — Judge James Robertson of the U.S. District Court for the District of Columbia has dismissed a private lawsuit challenging the appointment of Margaret Peterlin as Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the U.S. Patent and Trademark Office. The suit was brought by…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Abbott Laboratories v. Zydus Pharmaceuticals (USA), Inc.3:07-cv-05821; filed December 6, 2007 in the District Court of New Jersey Infringement of U.S. Patent…
-
December 13, 2007 – Pharmaceutical and Biotech Patent Law: Recent Developments (Practising Law Institute) January 4-8, 2008 – 25th Annual National CLE Conference (law Education Institute, Inc.) – Vail, CO January 9, 2008 – Patent Claim Construction (Law Seminars International) – San Francisco, CA January 25-26, 2008 – Buying, Selling and Licensing Patents: New Case…
Patent Docs 